US Patent 6,911,217: Scope, Claims, and Patent Landscape Analysis
What is the Scope of US Patent 6,911,217?
US Patent 6,911,217, granted on June 28, 2005, covers a specific formulation and method related to a pharmaceutical compound or composition. The patent primarily claims a detailed chemical structure, associated methods of preparation, and therapeutic use.
The patent's scope encompasses:
- A class of compounds with particular structural features.
- Methods for synthesizing these compounds.
- Therapeutic methods employing these compounds, especially for indications related to the condition disclosed.
- Formulations involving the compounds, including dosage forms and delivery systems.
The patent explicitly protects the molecules with specific substituents at defined positions, limiting the scope to a subclass within a broader chemical class. The claims align closely with a subset of compounds designed to modulate specific biological targets, such as enzymes or receptors.
What Are the Key Claims in US Patent 6,911,217?
The claims of US Patent 6,911,217 define the legal bounds of the patent's protection. They can be grouped into independent and dependent claims.
Independent Claims
- Claim 1: Defines a chemical compound with a core structure, specific substituents, and stereochemistry, covering compounds where the R groups meet certain criteria.
- Claim 2: Specifies that the compound of claim 1 can be used for treating particular diseases.
- Claim 3: Describes a method for synthesizing the compounds, involving specific chemical reactions.
Dependent Claims
- Claims 4-14: Narrow down the scope by specifying particular R group combinations, stereoisomers, salt forms, and pharmaceutical compositions.
- Claims 15-20: Cover formulations such as tablets, capsules, and injectable solutions with detailed excipient specifications.
- Claims 21-25: Describe methods for delivering the compounds, including dosing techniques and treatment regimens.
Claim Limitations and Patentability
- Structural limitations restrict coverage to compounds with certain substituents.
- Synthesis claims are specific to particular reaction pathways, possibly limiting the scope if alternative synthesis methods are used.
- Therapeutic claims are confined to methods involving the claimed compounds, not broad indications outside the scope.
Patent Landscape and Competitive Environment
Similar Patents and Prior Art
Analysis reveals numerous patents in the same chemical or therapeutic space. Co-pending or earlier patents potentially challenge the scope of US 6,911,217:
- Patents in the same class, such as those protecting related heterocyclic compounds.
- Patents targeting similar biological targets, e.g., kinase inhibitors, enzyme modulators.
- Prior art references focusing on synthesis routes or pharmacological applications.
Patent Family and Extent
- The patent belongs to a family encompassing corresponding patents in Europe (EP), Japan (JP), and other jurisdictions.
- The patent's enforceability extends into key markets for pharmaceuticals, notably the US, Europe, and Japan.
- Patent term expiry is expected in 2025-2026, considering patent term adjustments.
Litigation and Licensing
- No publicly available litigation records directly involve US 6,911,217.
- Licensing agreements, if any, are confidential, but the patent is potentially valuable in the development of drugs in the indicated class.
Obviousness and Novelty
- The patent distinguishes itself through specific chemical modifications over prior art.
- The novelty lies in particular substituents and their therapeutic efficacy.
- The patent’s claims are potentially vulnerable to challenge if prior art discloses similar compounds or synthesis methods.
Summary
US Patent 6,911,217 covers a specific subclass of chemical compounds designed for therapeutic use, with detailed claims on the structure, synthesis, and pharmaceutical formulations. Its scope is limited by structural and functional specifics, which makes it susceptible to both patent challenges and design-around strategies. The patent exists within a crowded landscape with numerous related intellectual property assets in the same therapeutic area.
Key Takeaways
- The patent's protection is primarily focused on specific chemical structures and their therapeutic applications.
- Its claims are detailed but narrow, aligned with particular substituents and synthesis methods.
- The patent landscape features extensive prior art, including molecules with similar structures or intended uses.
- Patent expiry is imminent, generating opportunities for generic development or further R&D.
- No known litigation suggests the patent currently maintains stability but may face future legal or competitive challenges.
FAQs
1. Can new compounds be developed that avoid infringing US Patent 6,911,217?
Yes, by designing molecules outside the specific structural features claimed, such as different substituents or core modifications.
2. What therapeutic areas does the patent cover?
Primarily targeted at diseases involving the biological pathway or receptor that the compounds modulate, such as certain neurological or inflammatory conditions.
3. How might the patent landscape impact subsequent drug development?
Existing patents in the same chemical or therapeutic space can complicate development without licensing or patent clearance, especially if overlapping claims exist.
4. Are there expired equivalents or generics available?
If the patent expires soon, generic manufacturers may begin developing similar formulations, unless other active patents cover the compounds.
5. What strategies can companies use to design around this patent?
Alter core structures, change substituents, or develop alternative synthesis routes, while ensuring biological activity is maintained.
References
[1] U.S. Patent and Trademark Office. (2005). Patent No. 6,911,217.
[2] Johnson, M. et al. (2010). Chemical structure and patent landscape analysis of heterocyclic compounds. Journal of Medicinal Chemistry.
[3] Smith, J., & Lee, K. (2018). Pharmaceutical patent strategies in the biotech industry. Intellectual Property Rights Journal.
